Meta-analysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: A HuGE-GSEC review

Genetics in Medicine

Volumn 10, Issue 6, 2008, Pages 369-384

  Varela Lema, Leonor ^a   Taioli, Emanuela ^b   Ruano Ravina, Alberto ^a   Barros Dios, Juan M ^a   Anantharaman, Devasena ^c   Benhamou, Simone ^d   Boccia, Stefania ^e   Bhisey, Rajani A ^f   Cadoni, Gabriella ^e   Capoluongo, Ettore ^e   Chen, Chien Jen ^g   Foulkes, William D ^h   Goloni Bertollo, Eny Maria ⁱ   Hatagima, Ana ^j   Hayes, Richard B ^k   Katoh, Takahiko ^l   Koifman, Sergio ^j   Lazarus, Phillip ^m   Manni, Johannes J ⁿ   Mahimkar, Manoj ^c   Morita, Shunji ^o   Park, Jong ^p   Park, Kwang Kyun ^q   Pavarino Bertelli, Erika Cristina ⁱ   De Souza Fonseca Ribeiro, Enilze Maria ^r   Roy, Bidyut ^s   Spitz, Margaret R ^t   Strange, Richard C ^u   Wei, Qingyi ^t   Ragin, Camille C ^b   more..

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c TATA MEMORIAL HOSPITAL   (India)

^d UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^e CATHOLIC UNIVERSITY   (Italy)

^f CANCER RESEARCH INSTITUTE   (India)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h MONTREAL GENERAL HOSPITAL   (Canada)

ⁱ School of Medicine ^*  (Brazil)

^j INSTITUTO OSWALDO CRUZ   (Brazil)

^k NATIONAL CANCER INSTITUTE   (United States)

^l KUMAMOTO UNIVERSITY   (Japan)

^m PENN STATE COLLEGE OF MEDICINE   (United States)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o Yao Municipal Hospital   (Japan)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q Yonsei University   (South Korea)

^r FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^s INDIAN STATISTICAL INSTITUTE   (India)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

CYP1A1; Epidemiology; GSTM1; Meta analysis and pooled analysis; Oral and pharyngeal cancers

Indexed keywords

CYTOCHROME P450 1A1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE TRANSFERASE;

AFRICAN AMERICAN; CANCER RISK; CAUCASIAN; EXON; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MOUTH CANCER; PHARYNX CANCER; REVIEW; SMOKING; ALLELE; ARTICLE; CASE CONTROL STUDY; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; META ANALYSIS; MOUTH TUMOR; RISK; TOBACCO DEPENDENCE;

NICOTIANA TABACUM;

ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; EXONS; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HOMOZYGOTE; HUMANS; MOUTH NEOPLASMS; ODDS RATIO; PHARYNGEAL NEOPLASMS; POLYMORPHISM, GENETIC; TOBACCO USE DISORDER;

EID: 48849104791     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181770196     Document Type: Review

References (120)

1. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
2. Geisler SA, Olshan AF. GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-huge review. Am J Epidemiol 2001;154:95-105.
3. Coles B, Ketterer B. The role of glutathione transferase in chemical carcinogenesis. Crit Rev Biochem Mol Biol 1990;25:47-70.
4. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ, et al. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of poly-cyclic aromatic hydrocarbons. Cancer Res 1989;49:6304-6312.
5. Coutelle C, Ward PJ, Fleury B, Quattrocchi P, et al. Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 1997;99:319-325.
6. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomark Prev 1997;6:733-743.
7. WiderstenM,PearsonWR,EngstromA,MannervikB. Heterologousexpressionoftheallelic variant mu-class glutathione S-transferase. Biochem J 1991;276(pt 2):519-524.
8. Strange RC, Fryer AA. The glutathione S-transferases: influence of polymorphism on cancer susceptibility. IARC Sci Publ 1999:231-244.
9. Sundberg K, Dreij K, Seidel A, Jernstrom B. Glutathione conjugation and DNA adduct formation of dibenzo[a]pyrene and benzo[a]pyrene diol epoxides in V79 cells stably expressing different human glutathione transferases. Toxicology 2002;15: 170-179.
10. Hasler JA. Pharmacogenetics of cytochromes P450. Mol Aspects Med 1999;20:12-137.
11. Nebert DW, Russell DW. Clinical importance of the cytochrome P450. Lancet 2002; 12:1155-1162.
12. Bartsch H, Nair U, Risch A, Rojas M, et al. Genetic polymorphism of CYP genes, alone or in combination as a risk modifier of tobacco related cancers. Cancer Epide-miol Biomark Prev 2000;9:3-28.
13. Romkes M, White C, Johnson J, Eibling D, et al. Expression of cytochrome P450 mRNA in human lung, head and neck tumors and normal adjacent tissues. Proc Am Assoc Cancer Res 1996;37:105.
14. Quan T, Reiners JJ Jr, Bell AO, Hong N, et al. Cytotoxicity and genotoxicity of-benzo-a-pyrene-trans-7,8-dihydrodiol in CYP1A1-expressing human fibroblasts quantitatively correlate with CYP1A1 expression level. Carcinogenesis 1994; 15:1827-1832.
15. Hilderbrand CE, Gonzalez FJ, McBride OW, Nebert DW. Assignment of the human 2,3,7,8-tetracholorodibenzo-p-dioxin inducible cytochrome P1-450 gene on chromosome 15. Nucleic Acids Res 1985;13:2009-2016.
16. Oscarson M, Ingelman S. CYPalleles: a web page for nomenclature of human cyto-chrome P450 alleles. Drug Metab Pharmacokinet 2002;17:491-495.
17. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte SJ, et al. Human cytochrome P-450 (CYP) genes: a web page for the nomenclature of alleles. Cancer Epidemiol Biomark Prev 2001;10:1307-1308.
18. Vineis P, Malats N, Lang M, dErrico A, et al, editors. Metabolic polymorphisms and susceptibility to cancer (IARC Scientific Publications No 148). Lyon, France: IARC, 1999.
19. Hayashi S, Watanabe J, Nakachi K, Kawajiri K. Genetic linkage of lung cancer associated MspI polymorphisms with amino acid replacement in the heme binding region of human cytochrome P4501A1 gene. J Biochem 1991;110:407-411.
20. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-4969.
21. KiyoharaC,HirohataT,InutsukaS. Therelationshipbetweenarylhydrocarbonhydroxylase and polymorphisms in the CYP1A1 gene. Jpn J Cancer Res 1996;87:18-24.
22. Zhang Z-Y, Fasco MJ, Huang L, Guengerich FP, et al. Characterization of purified human recombinant cytochrome P4501A1 Ile 462 and Val 462: assessment of a role for the rare allele in carcinogenesis. Cancer Res 1996;56:3926-3933.
23. Crofts F, Taioli E, Trachman J, Cosma GN, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-2963.
24. Rojas M, Alexandrov K, Cascorbi I, Brockmoller J. High benzo[a]pyrene diol-epox-ide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 Msp/MspI-GSTM1*0/*0 genotypes. Pharmacogenetics 1998;8:109-118.
25. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide IARC CancerBase,Version 2.0 No. 5. Lyon, IARCPress, 2004.
26. Bundgaard T, Wildt J, Frydenberg M, Elbrond O, et al. Case-control study of squamous cell cancer of the oral cavity in Denmark. Cancer Causes Control 1995;6:57-67.
27. La Vecchia C, Franceschi S, Favero A, Talamini R, et al. Alcohol intake and cancer of the upper digestive tract. Pattern of risk in Italy is different from that in Denmark. BMJ 1999;318:1289-1290.
28. Groenbaek M, Becker U, Johansen D, Tonnesen H, et al. Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract. BMJ 1998;317:844-847.
29. Castellsague X, Quintana MJ, Martínez MC, Nieto A, et al. The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer 2004;108:741-749.
30. Moreno-Lopez LA, Esparza-Gomez GC, Gonzalez-Navarro A, Cero-Lapiedra R, et al. Risk of oral cancer associated with tobacco smoking, alcohol consumption and oral hygiene: a case-control study in Spain. Oral Oncol 2000;36:170-174.
31. RosenquistK.Riskfactorsinoralandoropharyngealsquamouscellcarcinoma: apopulation based case-control study in southern Sweden. Swed Dent J Suppl 2005;179:1-66.
32. Altieri A, Bosetti C, Gallus S, Franceschi S, et al. Wine, beer and spirits and risks of oral and pharyngeal cancer: a case-control study from Italy and Switzerland. Oral Oncol 2004;40:904-909.
33. Lissowska J, Pilarska A, Pilarski P, Samolczyk-Wanyura D, et al. Smoking, alcohol, diet, dentition and sexual practices in the epidemiology of oral cancer in Poland. Eur J Cancer Prev 2003;12:25-33.
34. Garrote LF, Herrero S, Reyes RM, Vaccarella S, et al. Risk factors for cancer of oral cavity and oro-pharynx in Cuba. Br J Cancer 2001;85:46-54.
35. La Vecchia C, Tavani A, Franceschi S, Levi F, et al. Epidemiology and prevention of oral cancer. Oral Oncol 1997;33:302-312.
36. Herrero R, Castellsague X, Pawlita M, Lissowska J, et al. Human papillomavirus and oral cancer: the International Agency for Research on cancer multicentre study. J Natl Cancer Inst 2003;95:1772-1783.
37. Maden C, Beckmann AM, Thomas DB, McKnight B, et al. Human papillomavirus, herpes simplex viruses, and risk of oral cancer in men. Am J Epidemiol 1992;135: 1093-1102.
38. Mork J, Glattre E, Hallmans G, Jellum E, et al. Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N Engl J Med 2001; 344:1125-1131. (Pubitemid 32285233)
39. Hansson BG, Rosenquist K, Antonsson A, Wennerberg J, et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden. Acta Otolaryngol 2005;125:1337-1344. (Pubitemid 41722001)
40. Tripathy CB, Roy N. Meta-analysis of glutathione S-transferase M1 genotype and risk toward head and neck cancer. Head Neck 2006;28:217-224.
41. Hashibe M, Brennan P, Strange RC, Bhisey R, et al. Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1509-1517.
42. Ye Z, Song H, Guo Y. Glutathione S-transferase M1, T1 status and the risk of head and neck cancer: a meta-analysis. J Med Genet 2004;41:360-365.
43. Hung RJ, Boffetta P, Brockmoller J, Butkiewicz D, et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in caucasian non-smokers: a pooled analysis. Carcinogenesis 2003;24:875-882.
44. Matthias C, Bockmuhl U, Jahnke V, Jones PW, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998;8:91-100.
45. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, et al. High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 2000;60:534-536.
46. Mulder TPJ, Manni JJ, Roelofs HM, Peters WH, et al. Glutathione S-transferases and glutathione in human head and neck cancer. Carcinogenesis 1995;16:619-624.
47. Worrall SF, Corrigan M, High A, Starr D, et al. Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 1998;8:433-439.
48. Matthias C, Bockmuhl U, Jahnke V, Harries LW, et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 1998;8:1-6.
49. WenghoeferM,PeschB,HarthV,BroedeP,etal. Associationbetweenheadandneckcancer and microsomal epoxide hydrolase genotypes. Arch Toxicol 2003;77:37-41.
50. Cabelguenne A, Loriot MA, Stucker I, Blons H, et al. Glutathione- associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 2001;93:725-730.
51. Lee E, Huang Y, Zhao B, Seow-Choen F, et al. Genetic polymorphism of conjugating enzymes and cancer risk: GSTM1, GSTT1, NAT1 and NAT2. J Toxicol Sci 1998;23:140-142.
52. Amador AG, Righi PD, Radpour S, Everett ET, et al. Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:440-445.
53. Konig-Greger D, Riechelmann H, Wittich U, Gronau S. Genotype and phenotype of glutathione-S-transferase in patients with head and neck carcinoma. Otolaryngol Head Neck Surg 2004;130:718-725.
54. Evans AJ, Henner WD, Eilers KM, Montalto MA, et al. Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck 2004;26:63-70.
55. Park JY, Stimson PS, Lazarus P. Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype. Oral Oncol 2003;39:483-490.
56. McWilliams JE, Evans AJ, Beer TM, Andersen PE, et al. Genetic polymorphisms in head and neck cancer risk. Head Neck 2000;22:609-617.
57. Cheng L, Sturgis EM, Eicher SA, Char D, et al. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999;84:220-224.
58. Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2000;9:185-191.
59. Oude Ophuis MB, van Lieshout EM, Roelofs HM, Peters WH, et al. Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 1998;82:936-943.
60. Gaudet MM, Olshan AF, Poole C, Weissler MC, et al. Diet, GSTM1 and GSTT1 and head and neck cancer. Carcinogenesis 2004;25:735-740.
61. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 2003;128:674-680.
62. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, et al. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51: 294-298.
63. Trizna Z, Clayman GL, Spitz MR, Briggs KL, et al. Glutathione s-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.
64. Ko Y, Abel J, Harth V, Brode P, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001;61:4398-4404.
65. Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M, et al. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol 2008;134:93-100.
66. Biselli JM, de Angelo Calsaverini Leal RC, Ruiz MT, Goloni-Bertollo EM, et al. GSTT1 and GSTM1 polymorphism in cigarette smokers with head and neck squamous cell carcinoma. Rev Bras Otorrinolaringol (Engl Ed) 2006;72:654-658.
67. Goloni-Bertollo EM, Biselli JM, Correa LC, Maniglia JV, et al. [Evaluation of the influence of GSTT1 and GSTM1 null genotypes in head and neck carcinogenesis]. Rev Assoc Med Bras 2006;52:365-368.
68. Peters ES, McClean MD, Marsit CJ, Luckett B, et al. Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:2196-2202.
69. Capoluongo E, Almadori G, Concolino P, Bussu F, et al. GSTT1 and GSTM1 allelic polymorphisms in head and neck cancer patients from Italian Lazio Region. Clin Chim Acta 2007;376:174-178.
70. Park LY, Muscat JE, Kaur T, Schantz SP, et al. Comparison of GSTM polymor-phisms and risk for oral cancer between African-Americans and Caucasians. Phar-macogenetics 2000;10:123-131.
71. Hatagima A, Costa EC, Marques CF, Koifman RJ, et al. Glutathione S-transferase polymorphisms and oral cancer: a case-control study in Rio de Janeiro, Brazil. Oral Oncol 2008;44:200-207.
72. Marques CFS, Koifman S, Koifman RJ, Boffetta P, et al. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro. Oral Oncol 2006;42:632-637.
73. Sato M, Sato T, Izumo T, Amagasa T. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 1999;20:1927-1931.
74. Sato M, Sato T, Izumo T, Amagasa T. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol 2000;36:267-271.
75. Taioli E. International collaborative study on genetic susceptibility to environmental carcinogens. Cancer Epidemiol Biomark Prev 1999;8:727-728.
76. Gaspari L, Marinelli D, Taioli E. International collaborative study on Genetic Susceptibility to Environmental Carcinogens (GSEC): an update. Int J Hyg Environ Health 2001;204:39-42.
77. Katoh T, Kaneko S, Ohya R, Higashi K, et al. Glutathione S-transferase M1 gene polymorphism in patients with oral squamous cell carcinoma in relation to cigarette smoking. Asian J Oral Maxillofac Surg 1995;7:13-17.
78. Sikdar N, Paul RR, Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer 2004;109:95-101.
79. Xie H, Hou L, Shields PG, Winn DM, et al. Metabolic polymorphisms, smoking, and oral cancer in Puerto Rico. Oncol Res 2004;14:315-320.
80. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002;23:803-807.
81. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 1999;81:44-48.
82. Deakin M, Elder J, Hendrickse C, Peckham D, et al. Glutathione S-transferase GSTT1 genotype and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996;17:881-884.
83. Park JY, Muscat JE, Ren Q, Schantz SP, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 1997;6:791-797.
84. Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, et al. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis 2007;28:1455-1462.
85. Leichsenring A, Losi-Guembarovski R, Maciel ME, Losi-Guembarovski A, et al. CYP1A1 and GSTP1 polymorphisms in an oral cancer case-control study. Braz J Med Biol Res 2006;39:1569-1574.
86. Cha IH, Park JY, Chung WY, Choi MA, et al. Polymorphisms of CYP1A1 and GSTM1 genes and susceptibility to oral cancer. Yonsei Med J 2007;48:233-239.
87. Morita S, Yano M, Tsujinaka T, Akiyama Y, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 1999;80:685-688.
88. Kao SY, Wu CH, Lin SC, Yap SK, et al. Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancer lesions associated with smoking/betel use. J Oral Pathol Med 2002;31:505-511.
89. Kietthubthew S, Sriplung H, Au WW. Genetic and environmental interactions on oral cancer in Southern Thailand. Environ Mol Mutagen 2001;37:111-116.
90. Sreelekha TT, Ramadas K, Pandey M, Thomas G, et al. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001;37:593-598.
91. Nomura T, Noma H, Shibahara T, Yokoyama A, et al. Aldehyde dehydrogenase 2 and glutathione S-transferase M 1 polymorphisms in relation to the risk for oral cancer in Japanese drinkers. Oral Oncol 2000;36:42-46.
92. Tanimoto K, Hayashi S, Yoshiga K, Ichikawa T. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 1999;35:191-196.
93. Katoh T, Kaneko S, Kohshi K, Munaka M, et al. Genetic polymorphisms of tobacco-and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999; 83:606-609.
94. Kihara M, Kubota A, Furukawa M, Kimura H. GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett 1997;112:257-262.
95. Hung HC, Chuang J, Chien YC, Chern HD, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997;6:901-905.
96. Sharma A, Mishra A, Das BC, Sardana S, et al. Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. Neoplasma 2006;53:309-315.
97. Gattas GJ, de Carvalho MB, Siraque MS, Curioni OA, et al. Genetic polymorphisms CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. Head Neck 2006;28:819-826.
98. Drummond SN, De Marco L, Noronha JC, Gomez RS. GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol 2004;40:52-55.
99. Gronau S, Koenig-Greger D, Jerg M, Riechelmann H. GSTM1 enzyme concentration and enzyme activity in correlation to the genotype of detoxification enzymes in squamous cell carcinoma of the oral cavity. Oral Dis 2003;9:62-67.
100. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 2002;38:486-490.
101. Gupta C, Ray CS. Epidemiology of betel quid usage. Ann Acad Med Singapore 2004; 33(4 suppl):31S-36S.
102. Ragin CC, Taioli E, Weissfeld JL, White JS, et al. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 2006;95:1432-1438.
103. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, et al. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006; 31:259-266.
104. Taioli E, Gaspari L, Benhamou S, Boffetta P, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiology 2003; 32:60-63.
105. Rojas M, Cascorbi I, Alexandrov K, Kriek E, et al. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphisms. Carcinogenesis 2000;21:35-41.
106. Sram RJ. Effect of glutathione S-transferase M1 polymorphisms on biomarkers of exposure and effects. Environ Health Perspect 1998;106(suppl 1):231-239.
107. Ryberg D, Skaug V, Hewer A, Phillips DH, et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Car-cinogenesis 1997;18:1285-1289.
108. Weiserbs KF, Jacobson JS, Begg MD, Wang LW, et al. A cross-sectional study of polycyclic aromatic hydrocarbon-DNA adducts and polymorphism of glutathione S-transferases among heavy smokers by race/ethnicity. Biomarkers 2003;8:142-155.
109. Peluso M, Neri M, Margarino G, Mereu C, et al. Comparison of DNA adduct levels in nasal mucosa, lymphocytes and bronchial mucosa of cigarette smokers and interaction with metabolic gene polymorphisms. Carcinogenesis 2004;25:2459-2465.
110. Binkova B, Topinka J, Mrackova G, Gajdosova D, et al. Biomarkers in humans exposed to polycyclic aromatic hydrocarbons. Environ Mol Mutagen 1997;29(S28): S19-S23.
111. Mooney LA, Bell DA, Santella RM, Van Bennekum AM, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 1997;18:503-509.
112. Shields PG, Bowman ED, Harrington AM, Doan VT, et al. Polyciclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res 1993;53:3486-3492.
113. Pastorelli R, Guanci M, Cerri A, Negri E, et al. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA and blood protein adducts of benzo (a) pyrene-diolepoxide. Cancer Epidemiol Biomark Prev 1998;7:703-709.
114. Lodovici M, Luceri C, Guglielmi F, Bacci C, et al. Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1 and mEH. Cancer Epidemiol Biomark Prev 2004; 13:1342-1348.
115. Lai C, Shields PG. The role of interindividual variation in human carcinogenesis. J Nutr 1999;129(suppl):552S-555S.
116. Cheng YJ, Chien YC, Hildesheim A, Hsu MM, et al. No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2003;12:179-180.
117. Slattery ML, Samowtiz W, Murtaugh M, Sweeney C, et al. CYP1A1, cigarette smoking and colon and rectal cancer. Am J Epidemiol 2004;160:842-852.
118. Li D, Jiao L, Li Y, Doll MA, et al. Polymorphisms of cytochrome P4501A2 and N-actetyltransferase genes, smoking and risk of pancreatic cancer. Carcinogenesis 2006;27:103-111.
119. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y, et al. EPHX1 polymorphisms and the risk of lung cancer: a HUGE review. Epidemiology 2006;17:89-99.
120. Zheng Z, Park JY, Guillemette C, Schantz SP, et al. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 2001;93:1411-1418.